Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

DNTH

Live52w high -10.0%

Annual Quarterly

Core line items from DNTH's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Log in Get Started

Annual Quarterly

Financial statements

Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.

Entity: Dianthus Therapeutics, Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-05	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31
Revenue	$277.99K	$2.04M	$1.75M	$1.36M	$1.16M
Operating Income	Not available	$-177.93M	$-108.39M	$-68.10M	$-33.18M
Net Income	Not available	$-162.34M	$-97.91M	$-31.63M	$-29.51M
EPS (Diluted)	$-0.89	$-4.20	$-2.68	$-1.71	$-0.82
Total Assets	Not available	$530.92M	$577.45M	$326.08M	$348.58M
Total Liabilities	Not available	$37.52M	$30.99M	$23.00M	$19.97M
Cash & Equivalents	Not available	$51.09M	$55.98M	$13.24M	$10.12M
Free Cash Flow OCF − CapEx	Not available	$-129.27M	$-82.15M	$-51.59M	$-27.65M
Shares Outstanding	Not available	43.22M	42.85M	32.18M	32.13M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from DNTH's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -10.0%

Financial statements

Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.

Entity: Dianthus Therapeutics, Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-05	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31
Revenue	$277.99K	$2.04M	$1.75M	$1.36M	$1.16M
Operating Income	Not available	$-177.93M	$-108.39M	$-68.10M	$-33.18M
Net Income	Not available	$-162.34M	$-97.91M	$-31.63M	$-29.51M
EPS (Diluted)	$-0.89	$-4.20	$-2.68	$-1.71	$-0.82
Total Assets	Not available	$530.92M	$577.45M	$326.08M	$348.58M
Total Liabilities	Not available	$37.52M	$30.99M	$23.00M	$19.97M
Cash & Equivalents	Not available	$51.09M	$55.98M	$13.24M	$10.12M
Free Cash Flow OCF − CapEx	Not available	$-129.27M	$-82.15M	$-51.59M	$-27.65M
Shares Outstanding	Not available	43.22M	42.85M	32.18M	32.13M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.